Linagliptin Krka (Linagliptin)

Linagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prevents the breakdown of incretin hormones such as GLP‑1 and GIP, leading to increased insulin secretion in response to meals, reduced glucagon release, and overall better regulation of blood glucose levels.

The exact dose of Linagliptin Krka is determined by the prescribing healthcare professional based on the individual patient's clinical condition, renal and hepatic function, and concomitant therapies. Prescribers typically start with a standard dose and may adjust it according to therapeutic response and tolerability.

Safety data for Linagliptin Krka in pregnancy and lactation are limited. It should only be used if the potential benefits justify the potential risks to the fetus or infant. Healthcare providers usually recommend alternative treatments with established safety profiles for pregnant or nursing women.

To order Linagliptin Krka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors but has a distinct pharmacokinetic profile, allowing once‑daily dosing without the need for renal dose adjustment. This can be advantageous for patients with mild to moderate renal impairment, whereas some other agents require dose reductions based on kidney function.

Linagliptin Krka should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Linagliptin Krka is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the timing without medical advice.

The most serious risks include pancreatitis, which presents as severe abdominal pain, and severe allergic reactions such as rash, angioedema, or anaphylaxis. When combined with insulin or sulfonylureas, there is also an increased risk of hypoglycaemia. Patients should seek immediate medical attention if any of these symptoms occur.

Linagliptin Krka should not be used by individuals with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is advised for patients with severe hepatic impairment, and it is generally avoided in patients with a history of pancreatitis until further evaluation by a physician.